2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2025
0mins
Should l Buy ?
Source: Yahoo Finance
Innovent Biologics Presentation: Innovent Biologics announced the presentation of preclinical data on novel bispecific and tri-specific antibodies, as well as bispecific antibody-drug conjugates (ADCs), at the AACR Annual Meeting 2025, showcasing advancements in their oncology pipeline aimed at treating difficult-to-treat cancers.
Research Highlights: Key research findings include IAR037, a bispecific antibody for immune checkpoint inhibitor-resistant tumors, and IBI3010, an ADC targeting FRα expressing tumors, both demonstrating promising efficacy and safety profiles in preclinical studies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
